A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.
Evotec receives US contract for antibody development
Just – Evotec Biologics will focus on developing drug product prototypes from the discovery stage to the launch of first-in-human Phase I clinical trials. Credit:
July 6, 2023